The Most Comprehensive Review of Medical Cannabis Evidence Found Modest Benefits for Pain, Spasticity, and Nausea

The Review

Whiting's team searched 28 databases — not just PubMed and MEDLINE, but dozens of specialized repositories — for every randomized controlled trial of cannabinoids for any medical indication, from the earliest databases through April 2015. They included trials of all cannabinoid formulations: smoked cannabis, pharmaceutical THC (dronabinol), synthetic THC (nabilone), THC:CBD spray (nabiximols/Sativex), and oral CBD.

They found 79 trials involving 6,462 participants. Only four were rated at low risk of bias.

That last number is worth pausing on. By 2015, tens of millions of people were using cannabinoids therapeutically. The total number of patients ever enrolled in a randomized trial of any cannabinoid for any condition: 6,462. For context, a single large pharmaceutical trial for a new blood pressure drug might enroll more participants than the entire global history of cannabinoid RCTs combined.

What The Evidence Showed

The pattern was clear: moderate evidence for three conditions (pain, spasticity, chemotherapy nausea), low-quality evidence for a few more, and insufficient evidence for most of the conditions that patients were actually using cannabis to treat. The effects that did reach significance were often modest — a pain reduction of 0.46 points on a 10-point scale is real but not dramatic.

The Pain Numbers, Honestly

The pillar article describes roughly 30% of patients achieving meaningful pain relief with cannabinoids versus 20% on placebo. That gives a number needed to treat (NNT) of about 10 — meaning you need to treat 10 patients before one gets meaningful relief beyond placebo.

These numbers don't make cannabinoids look like miracle drugs. But they don't make them look useless either. For the subset of patients who respond — and particularly for those who have failed other treatments — the modest average effect conceals genuine individual benefit. And cannabinoids have a safety advantage over long-term opioid use that the NNT doesn't capture.

The honest assessment: cannabinoids for chronic pain are a legitimate option, not a first-line treatment. They work modestly for some people, particularly for neuropathic pain. The evidence base supporting their use is thinner than it should be, but it's real.

The Side Effects

Why This Study Changed the Conversation

The Whiting review was uncomfortable for everyone. Cannabis advocates couldn't cite it as proof that cannabis is medicine — the evidence was modest and the evidence base was thin. Cannabis opponents couldn't cite it as proof that cannabis doesn't work — the effects for pain, spasticity, and nausea were real. Policymakers got the answer they didn't want: "it's complicated, and we don't have enough trials."

Myth vs. Reality

✕Myth

Thousands of studies prove medical cannabis works.

✓Reality

By 2015, only 79 randomized controlled trials of cannabinoids for any medical condition had ever been conducted worldwide, involving a total of 6,462 participants. Only 4 met low-risk-of-bias standards. The evidence supports cannabinoids for a few specific conditions (chronic pain, spasticity, chemo nausea) with moderate quality, while evidence for most other conditions remains insufficient.

The Evidence

Whiting et al. searched 28 databases comprehensively. The 'thousands of studies' cited by advocates include preclinical research (cell and animal studies), observational studies, case reports, and reviews — not the randomized trials that constitute the strongest evidence for therapeutic efficacy.

Whiting et al. (2015), JAMA

The review became the reference document for the 2017 National Academies report on cannabis, which used it as a foundation for its own evidence assessments. It remains the most-cited systematic review of cannabinoid therapeutics — not because its findings were dramatic, but because it was honest about what we know and don't know.

For patients considering medical cannabis, the Whiting review's legacy is a framework for realistic expectations: cannabinoids can help, modestly, for specific conditions. They're not a panacea. And the evidence base, while growing, remains far thinner than what exists for most prescription drugs. For a detailed look at what the evidence supports, see our guide to the evidence-based medical benefits of cannabis and the specific research on cannabis and chronic pain.

Frequently Asked Questions

Does this study prove medical cannabis works?

It provides moderate-quality evidence that cannabinoids help with chronic pain, MS spasticity, and chemotherapy nausea. For other conditions, the evidence was insufficient or low-quality. "Works" depends on the condition and what you mean by "works" — the effects are real but modest for the best-supported indications.

Why were there so few trials?

Cannabis's Schedule I status in the United States made clinical research extremely difficult — researchers needed DEA licenses, could only use government-supplied cannabis (often of poor quality), and faced institutional barriers. Other countries had similar regulatory obstacles. The result: one of the most widely used therapeutic substances in the world had almost no high-quality clinical trial data.

Do these findings apply to dispensary cannabis?

Partially. Most trials used pharmaceutical-grade products (dronabinol, nabilone, nabiximols) with precise dosing. Dispensary products have variable potency, different cannabinoid ratios, and additional compounds (terpenes, minor cannabinoids) not present in pharmaceutical formulations. The assumption that dispensary products produce identical results is common but unproven.

Has the evidence improved since 2015?

Yes, substantially. The Epidiolex trials for epilepsy (2017-2018), the Wang et al. BMJ chronic pain review (2021), and several Sativex trials for MS have added to the evidence base. But the fundamental picture — modest effects for specific conditions, insufficient evidence for most — remains largely accurate.